

medcann licences the use of its cannabis strains to an international client, evidencing the quality of its genetic bank.

- **Colombia is set to become a world powerhouse in research, development and protection of intellectual property of new strains of cannabis seeds for medicinal use.**

Bogotá, April 6th, 2020. medcann Colombia SAS, an affiliate of the Canadian holding medcann Pharma Inc. ("medcann"), a leader in the cannabis industry for medical use and research, continues to mark milestones. This time, taking advantage of the strength of Colombia's regulatory framework, medcann will make available to the Canadian firm Klonetics Plant Science Inc. ("Klonetics") different psychoactive and non-psychoactive cannabis strains as starting material, to be used, developed and commercialized - exclusively - in Canada, Australia and New Zealand.

"It is important to note that this historic agreement highlights Colombia's potential as a supplier of different strains of cannabis for medicinal use for the world, as is Holland in the field of flowers," explains Jon Ruiz, president of medcann.

The agreement provides for a payment in shares and stock options of Klonetics in addition to a percentage of the revenue from sales of the different strains. This agreement significantly accelerates medcann's international research and development plan, developing a long-term partnership with Klonetics that will undertake a joint hybridization program between the two companies.

For Klonetics, a Canadian company that is consolidating an international genetics center to expand the cannabis research field, this agreement will allow it to display genetics originating in an authority-certified supplier as is medcann.

The news comes at a time when the world faces major economic challenges due to the effects of the **Covid-19** pandemic, and shows the possibilities of this industry to create jobs, up to 100 thousand new jobs, and contribute to improving the balance of trade, as established by a study carried out by the firm Econcept (September 2019), of former ministers Juan Carlos Echeverry, Tomás González and Mauricio Santamaría.



"It is time to strengthen the areas of the economy that can provide a very important lifeline for the country, with a regulated product that could provide an income tax collection between 1.02 and 3.5 trillion pesos and that offers the country an exceptional opportunity to increase the weight of exports in GDP and diversify them with a new product such as cannabis for medicinal use," concludes Jon Ruiz.

About medcann: Canadian holding company, with international presence, which aspires to be a global supplier and produce 100% organic cannabis extracts with energy from renewable sources, certified for medicinal use, in an innovative, responsible and sustainable way. We guarantee the highest possible quality for the development of therapeutic solutions that contribute to improving the lives of people around the world. We seek to be the largest and most profitable outdoor medicinal cannabis operator and to build one of the largest genetic banks in the world. To this end, we are committed to working together with health professionals, patients, governments, organizations, technology partners and investors. Our activities promote policies and initiatives that promote and protect health and equity in people's access to therapeutic solutions.

To learn more about our operations visit: www.medcann.com

Cannabis economic impact study in Colombia, sponsored by medcann:

<https://drive.google.com/file/d/1qUYgSEpMQVSinIHSmwlyZwi2eQxl2g6-/view?usp=sharing>

Press Contact:

Lucia Esparza Baena – Director of Communications and Corporate Affairs

Telephone: 3132093275

Email: lucia.esparza@medcann.com.co

Teléfono: (+571) 555 2951 ● Dirección: Calle 75#8-59



www.medcann.com